Fintel reports that on February 13, 2025, Leerink Partners upgraded their outlook for Genmab A (NasdaqGS:GMAB) from Market Perform to Outperform.
Analyst Price Forecast Suggests 558.90% Upside
As of January 29, 2025, the average one-year price target for Genmab A is $129.74/share. The forecasts range from a low of -$143.01 to a high of $236.71. The average price target represents an increase of 558.90% from its latest reported closing price of $19.69 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Genmab A is 22,486MM, an increase of 4.46%. The projected annual non-GAAP EPS is 126.42.
What is the Fund Sentiment?
There are 258 funds or institutions reporting positions in Genmab A. This is an decrease of 13 owner(s) or 4.80% in the last quarter. Average portfolio weight of all funds dedicated to GMAB is 0.07%, an increase of 0.14%. Total shares owned by institutions increased in the last three months by 10.43% to 64,568K shares. 
The put/call ratio of GMAB is 0.62, indicating a bullish outlook.
What are Other Shareholders Doing?
Alliancebernstein holds 14,935K shares. In its prior filing, the firm reported owning 15,136K shares , representing a decrease of 1.35%. The firm decreased its portfolio allocation in GMAB by 33.62% over the last quarter.
APGAX - AB LARGE CAP GROWTH FUND INC holds 4,509K shares. In its prior filing, the firm reported owning 4,581K shares , representing a decrease of 1.59%. The firm decreased its portfolio allocation in GMAB by 23.12% over the last quarter.
IBB - iShares Nasdaq Biotechnology ETF holds 4,123K shares. In its prior filing, the firm reported owning 4,196K shares , representing a decrease of 1.78%. The firm decreased its portfolio allocation in GMAB by 7.21% over the last quarter.
Harding Loevner holds 3,067K shares. In its prior filing, the firm reported owning 2,768K shares , representing an increase of 9.75%. The firm increased its portfolio allocation in GMAB by 12.24% over the last quarter.
Capital International Investors holds 2,571K shares. In its prior filing, the firm reported owning 4,422K shares , representing a decrease of 71.99%. The firm decreased its portfolio allocation in GMAB by 51.42% over the last quarter.
Genmab Background Information
(This description is provided by the company.)
Genmab A/S is a Danish biotechnology company, founded in February 1999 by Florian Schönharting, at the time managing director of BankInvest Biomedical venture fund.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
